Skip to main content

Table 4 Summary of 24-hour urine glucose (mmol) on day 2 by treatment

From: Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

 

Met BID

RE BID

Met + RE BID

N = 13

N = 13

N = 13

Mean (SD)

13.6 (13.4)

528 (130)

458 (98)

Median

10.9

497

485

Min, Max

1.1, 43.9

384, 796

242, 573

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us